STA®-Liquid Fib is the lastest innovation in our routine line. This new liquid reagent for the quantitative determination of fibrinogen levels is based on the reference Clauss clotting method combined with the mechanical clot detection system. STA®-Liquid Fib is a practical and robust reagent designed to give reliable results.
Read more
STA Compact Max®: Innovation born from Expertise
STA Compact Max® is the new generation of analyser developed by the Coagulation Company to meet labs' expectations.
Read more
STA®-ImmunoDef VIII & STA®-ImmunoDef IX
As part of Stago's continuous improvement commitment, STA®-ImmunoDef VIII* & STA®-ImmunoDef IX* kits have been developed as a new generation of Deficient Plasmas with enhanced performances. Factors VIII and IX measurement allows characterising clinically significant conditions such as Haemophilia A and B. Robust and reliable reagents should be available for an easier daily laboratory practice.
Read more
New range of STA®-Routine QC quality control plasmas: The best range for routine laboratory tests
To fulfil regulatory requirements, laboratories must perform regular internal quality control (IQC) on at least two concentration levels (normal and abnormal) to check and confirm the performance of their testing systems.
Read more
STA®-Rivaroxaban Calibrator & STA®-Rivaroxaban Control
Rivaroxaban is an oral anticoagulant, direct factor Xa inhibitor, developed by Bayer HealthCare and sold under the trade name Xarelto®. It is approved in three indications in Europe: prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (AF) with one or more risk factors, treatment of deep vein thrombosis (DVT) and prevention of recurrent DVT and pulmonary embolism (PE) following an acute DVT in adults and prevention of VTE in adult patients undergoing elective hip or knee replacement surgery.
Read more